Specialists at the Microbial Therapy Research Department of the WCRC for Personalized Medicine earlier isolated unique Streptococcus pyogenes (S. pyogenes) strains, M49 and M111, with oncolytic properties in the cells of hepatoma, sarcoma, pancreatic and brain cancers. The surface structures of strains have a cytotoxic (damaging) effect on tumor cells.
However, studies were needed to investigate the possibility of using live bacterial cells for the treatment of tumors. The toxicity of oncolytic S. pyogenes against normal cells was studied in the in vivo system and in vitro on the model of a cell line of normal human fibroblasts.
The studies were carried out using the modern xCELLigence real-time cell monitoring system.
For more, read the news of the WCRC for Personalized Medicine.